---
layout: default
title: Alfuzosin Hcl
parent: 僅模型預測 (L5)
nav_order: 62
evidence_level: L5
indication_count: 0
---

# Alfuzosin Hcl
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alfuzosin HCL: Repurposing Evaluation — Insufficient Data to Complete Assessment

## One-Sentence Summary

Alfuzosin HCL is a pharmaceutical compound; however, this Evidence Pack contains **no original indication data**, **no TxGNN-predicted new indications**, and **no safety information**.
Without predicted indications or mechanism data, a standard repurposing evaluation cannot be completed at this stage.
**All core inputs are missing — a Hold decision is mandatory until data collection is complete.**

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in this Evidence Pack |
| Predicted New Indication | None — no predictions generated |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 (no studies; no model prediction output) |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why a Full Assessment Cannot Be Completed

This Evidence Pack is missing all three inputs required to complete a repurposing analysis:

1. **No mechanism of action (MOA) data.** The DrugBank query returned a result (`result_count: 1`), but no MOA was extracted. This blocks the mechanistic rationale section entirely.

2. **No predicted indications.** The `predicted_indications` array is empty, meaning TxGNN did not produce — or did not successfully populate — any repurposing candidates for Alfuzosin HCL in this run. Without a target indication, the clinical trial evidence, literature evidence, and prediction rationale sections cannot be written.

3. **No approved indication on record.** The original indication list is empty and the Singapore HSA database shows zero registrations, so even the drug's established therapeutic role cannot be confirmed from this pack alone.

Currently, detailed mechanism of action data is not available. Based on its INN suffix (`-zosin`), Alfuzosin likely belongs to the alpha-1 adrenergic receptor blocker class — but **this must be verified from DrugBank before being used in any evaluation**.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Singapore Market Information

Alfuzosin HCL has **zero HSA registrations** in Singapore and is listed as **not marketed**. There are no authorisation records to display.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is missing predicted indications, approved indications, mechanism of action, and all safety data — the minimum viable inputs for a repurposing evaluation are not present, and proceeding would produce a report with no evidential basis.

**To proceed, the following is needed:**

- **Re-run TxGNN prediction** for Alfuzosin HCL and confirm that `predicted_indications` is populated before generating the next report version
- **Retrieve DrugBank record** — the query log shows a successful hit (`result_count: 1`); extract `drugbank_id`, MOA, drug categories, and toxicity data
- **Confirm original approved indication(s)** — check TFDA, EMA, or FDA label for the registered indication (likely benign prostatic hyperplasia based on drug class, but must be verified)
- **Retrieve safety information** — download and parse the prescribing information PDF to extract warnings, contraindications, and drug-drug interactions
- **Verify Singapore HSA status** — confirm whether the drug is intentionally absent from the Singapore market or whether the query failed to match the correct entry (consider searching by brand name or partial INN)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

